The attitude of women toward current and future possibilities of diagnostic testing in maternal blood using fetal DNA

  title={The attitude of women toward current and future possibilities of diagnostic testing in maternal blood using fetal DNA},
  author={Loes Kooij and Tjeerd Tymstra and P. van den Berg},
  journal={Prenatal Diagnosis},
To determine the opinions of women about the new developments in the field of noninvasive prenatal diagnosis (NIPD). 
This paper presents a meta-analyses of the determinants of infectious disease in eight operation rooms and shows clear patterns of infection that are consistent with those found in the literature on infectious disease and wound care.
Attitudes toward non‐invasive prenatal diagnosis among pregnant women and health professionals in Japan
This study aims to assess the attitudes toward non‐invasive prenatal diagnosis (NIPD) and NIPD problems in clinical practice in Japan.
Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening
The aim of this study was to investigate how the introduction of noninvasive prenatal testing (NIPT) impacted women's testing choices following a positive prenatal screening (PNS) result.
Noninvasive prenatal diagnosis: pregnant women's interest and expected uptake
To investigate pregnant women's level of future interest in noninvasive prenatal diagnosis (NIPD) and what factors might affect expected uptake of this testing.
Routine testing of fetal Rhesus D status in Rhesus D negative women using cell-free fetal DNA: an investigation into the preferences and information needs of women
The goal of this study is to investigate women's preferences and information needs for routine implementation of fetal Rhesus D (RhD) typing using cell‐free fetal DNA.
Noninvasive prenatal testing for aneuploidy-ready for prime time?
Fetal sex determination using cell‐free fetal DNA: service users' experiences of and preferences for service delivery
The aim of this study was to determine service users' experiences of and preferences for service delivery of fetal sex determination by noninvasive prenatal diagnosis (NIPD) using cell‐free fetal DNA.
NIPT : non-invasive prenatal testing : towards implementation in the Netherlands
NIPT is already clinically available in many countries, yet many research questions remain unanswered. In this thesis, important aspects for implementation are addressed. The main conclusions are
Women's uptake of non‐invasive DNA testing following a high‐risk screening test for trisomy 21 within a publicly funded healthcare system: findings from a retrospective review
The objective of the study was to evaluate the uptake of non‐invasive cell‐free fetal DNA screening test (NIDT) after a high‐risk screening result for trisomy 21
Non-invasive prenatal testing: ethics and policy considerations.


Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one‐stop clinic: a review of three years prospective experience
The performance of a one‐stop multidisciplinary clinic of screening for fetal chromosomal anomalies in the first trimester of pregnancy by a combination of maternal serum biochemistry and ultrasonography is evaluated.
Prenatal detection of a cystic fibrosis mutation in fetal DNA from maternal plasma
The possibility of performing the detection of a single‐gene disorder such as a fetal paternally inherited Cystic Fibrosis mutation (Q890X) in maternal plasma is assessed.
How women deal with the results of serum screening for Down syndrome in the second trimester of pregnancy
In insight into how pregnant women experience serum screening for Down syndrome, questionnaires were sent to two groups of relevant subjects in the north of the Netherlands and it was considered that second trimester serum screening made a welcome contribution to the decision‐making process about whether to undergo amniocentesis.
Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection
This work achieved noninvasive prenatal diagnosis of fetal trisomy 21 by determining the ratio between alleles of a single-nucleotide polymorphism (SNP) in PLAC4 mRNA, which is transcribed from chromosome 21 and expressed by the placenta, in maternal plasma.
Women's opinion on the use and offer of ovarian reserve testing: A First step towards a wide ranged social discussion
The ability to determine the individual ovarian reserve makes this test also a suitable device for family planning, and the outcome of the study does not support this: even low chances of success are found acceptable.
Presence of fetal DNA in maternal plasma and serum
Huntington disease–unaffected fetus diagnosed from maternal plasma using QF‐PCR
This work has successfully diagnosed, with a non‐invasive procedure, an unaffected HD fetus at the 13th week of gestation using fetal DNA from maternal plasma and the quantitative fluorescent PCR method, which is one of the most sensitive ways to detect fetal DNA in maternal plasma at such an early time of gestation.
Prenatal diagnosis of myotonic dystrophy using fetal DNA obtained from maternal plasma.
The possibility of using maternal plasma for prenatal diagnosis of DM was evaluated by monitoring the pregnancy of an unaffected woman whose husband was affected by DM (70 CTG repeats); all participants gave oral and written informed consent.